Vaxart (NASDAQ:VXRT) Stock Passes Below 200-Day Moving Average - Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.56 and traded as low as $0.46. Vaxart shares last traded at $0.46, with a volume of 1,225,503 shares changing hands.

Analyst Ratings Changes

VXRT has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Vaxart to a "hold" rating in a report on Thursday, May 22nd. B. Riley lowered their price objective on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating on the stock in a report on Thursday, March 27th.

Vaxart Stock Down 6.5%

The company has a market capitalization of $99.69 million, a price-to-earnings ratio of -1.07 and a beta of 1.27. The stock's fifty day moving average price is $0.40 and its 200-day moving average price is $0.56.

Vaxart (NASDAQ:VXRT - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07). The business had revenue of $20.88 million for the quarter, compared to the consensus estimate of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. Analysts anticipate that Vaxart, Inc. will post -0.39 EPS for the current year.

Insider Buying and Selling

In related news, insider Steven Lo acquired 100,000 shares of the firm's stock in a transaction on Monday, May 19th. The shares were purchased at an average cost of $0.49 per share, for a total transaction of $49,000.00. Following the completion of the acquisition, the insider now directly owns 100,000 shares in the company, valued at approximately $49,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vaxart

A number of institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new stake in shares of Vaxart in the first quarter valued at about $31,000. Jones Financial Companies Lllp boosted its position in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock valued at $196,000 after acquiring an additional 478,111 shares during the period. Virtu Financial LLC bought a new stake in shares of Vaxart in the first quarter valued at about $56,000. Invesco Ltd. boosted its position in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after acquiring an additional 70,568 shares during the period. Finally, Squarepoint Ops LLC boosted its position in shares of Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after acquiring an additional 251,789 shares during the period. Institutional investors own 18.05% of the company's stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.